Assessment of the Neutrophil-Lymphocyte Ratio in Classic Hodgkin Lymphoma Patients

Ali Dogan¹, Sinan Demircioglu²

ABSTRACT

Background and Objective: Besides known risk scoring systems, studies have recently been conducted in relation to NLR to estimate the prognosis of HL. Some studies found a relationship of NLR with PFS and OS. Our objective was to investigate whether NLR, as an inexpensive and easily accessible test, is a prognostic marker for cHL, as in several previous studies.

Methods: The study included 232 patients in the age range of 18 to 88 years who were diagnosed with classic Hodgkin Lymphoma and received ABVD chemotherapy and/or radiotherapy at Van Yuzuncu Yil University Hematology Clinic from 2000-2018. Analyses were conducted on the disease stage, risk scores, treatment responses and relapse statuses at the time of diagnosis based on the patients' NLR values at the time of diagnosis.

Results: The mean age of the patients was 39.27 ± 15.90, while 38.8% were female and 61.2% were male. The NLR value at the time of diagnosis was significantly related to stage (p:0.013), early-stage risk score (p:0.022) and treatment response (p:0.032). The cutoff value of NLR was found as 4.23. The Hb value at the time of diagnosis was significantly related to stage (p:0.00), early-stage risk score (p:0.007), treatment response (p:0.006) and the latest status of patients (p:0.005).

Conclusion: High NLR values were found to be significantly related to disease stage, early-stage risk scoring and response to the treatment. These findings need to be supported by prospective studies with larger samples for these data to be used prognostic scores.

KEYWORDS: Hodgkin lymphoma, Lymphocyte, Neutrophil, Neutrophil-lymphocyte ratio, Prognosis, Stage.

doi: https://doi.org/10.12669/pjms.35.5.601

How to cite this:
Dogan A, Demircioglu S. Assessment of the Neutrophil-Lymphocyte Ratio in Classic Hodgkin Lymphoma Patients. Pak J Med Sci. 2019;35(5):1270-1275. doi: https://doi.org/10.12669/pjms.35.5.601

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Hodgkin lymphoma (HL) is a rare malignancy that involves lymph nodes and the lymphatic system. Most patients are diagnosed between the ages of 15 and 30, and a second peak is observed in adults of 55 years of age or older.¹ The World Health Organization (WHO) classifies HL into two main groups as classic Hodgkin lymphoma (cHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL).² Among all HL cases in Western countries, 95% correspond to cHL, while 5% correspond to NLPHL. cHL has 4 sub-types as nodular sclerosis classic HL (NSHL), mixed cellularity classic HL (MCHL), lymphocyte rich classic HL (LRHL) and lymphocyte depleted classic HL (LDHL).
The prognostic factors of early-stage HL were defined as the presence of a large mediastinal mass, high sedimentation rate, involvement of multiple modal regions, extra-nodal involvement, age of older than 50 years or presence of a massive splenic disease.3,4 For advanced-stage HL, an international prognostic scoring system which consists of seven variables (age >45, presence of stage-4 disease, male sex, leukocytosis >15,000/mm³, lymphopenia <600/mm³, albumin <4.0 g/dL, hemoglobin (Hb) <10.5 g/dL) was defined.5 These diagnostic scoring systems are used in both predicting the course of the disease and planning treatment.

The prognostic significance of the neutrophil/lymphocyte ratio (NLR) is known in recent times in relation to some solid organ malignity cases. It was shown that NLR is a prognostic factor in diffuse large B-cell lymphoma (DLBCL).6-8 In addition to this, a few studies have examined the potential prognostic value of NLR in cHL.9-11 The aim of this study was to investigate whether NLR, as an inexpensive and easily accessible test, is a prognostic marker for cHL, as in several previous studies.

METHODS

Study design: The study included 232 patients in the age range of 18 to 88 years who were diagnosed with classic Hodgkin Lymphoma and received ABVD chemotherapy and/or radiotherapy. The patients’ demographic data, stages at the time of diagnosis based on the Ann Arbor classification, risk groups, laboratory values, treatment responses, relapse statuses and latest statuses were determined retrospectively. Stages-1 and 2 were defined as early stage, while stages-3 and 4 were defined as advanced stage. The prognostic classification of early stages was made by the risk classification of the European Organization for the Research and Treatment of Cancer (EORTC).12 Negative risk factor was defined as the presence of at least one of these criteria: age (>50), sedimentation (>50 mm/s), mediastinal thorax rate (MTR) (>0.35) and/or number of nodal regions (>4). The advanced stage classification was made by the international prognostics scoring (IPS) method.5 Negative risk factor was defined as at least three of these criteria: albumin (<4 g/dl), Hb (<10.5 g/dl), male sex, age (>45), stage-4 disease, leukocytosis (>15,000/mm³) and/or lymphopenia (<600/mm³).

Statistical analysis: While our study expresses the continuous variables with their descriptive characteristics as mean, standard deviation, minimum and maximum values, the categorical variables are expressed in terms of frequencies and percentages. NLR was found by dividing the number of neutrophils by the number of lymphocytes. While analyzing the data, Kolmogorov-Smirnov normality test was used to determine the suitability of the continuous variables for normal distribution. The data that were normally distributed were analyzed by using independent-samples t-test, while the non-normally distributed data were analyzed by using Mann-Whitney U test. The threshold values of NLR and Hb were determined by ROC curve analysis. A p-value of <0.05 was accepted to be statistically significant. The analyses were carried out using SPSS 24.

Ethics committee approval: The study was approved by the Van Yuzuncu Yil University Local Ethics Committee (protocol number: 09.11.2018/08).

RESULTS

The study included 232 patients who were diagnosed with classic Hodgkin Lymphoma. The mean age of the patients was found as 39.27 ± 15.90. The age histogram is shown in Fig.1. The disease stages, prognostic characteristics, treatment

Fig.1: Distribution by age at diagnosis.
The NLR value at the time of diagnosis was significantly related to stage (p:0.013), early-stage risk score (p:0.022) and treatment response (p:0.032). It had no significant relationship with disease prognostic characteristics (p:0.38), relapse status (p:0.51) or latest status (p:0.87) regarding the advanced stages. The mean NLR value was found as 3.94 ± 3.70 in the early stages and 5.91 ± 6.56 in the advanced stages. While the mean NLR value was found as 2.77 ± 1.61 in the group with early-stage positive prognostic characteristics, it was found as 4.58 ± 0.51 in the early-stage negative risk group. This value for the group that responded to the treatment (CR+PR) was 4.97 ± 5.76, while it
was 5.63 ± 4.09 in the group that did not respond (Table-III).

The ROC analysis demonstrated an area under the curve (AUC) of 0.625 (Fig.2). A cut-off value of 4.23 for NLR was able to predict treatment response rate with a sensitivity and specificity of 60% and 65%, respectively (likelihood ratio-LR=1.72).

The ROC analysis demonstrated an area under the curve (AUC) of 0.662 (Fig.3). A cut-off value of 12.25 g/dl for Hb was able to predict treatment response rate with a sensitivity and specificity of 59% and 61%, respectively (likelihood ratio-LR=1.50).

The Hb value at the time of diagnosis was also significantly related to stage (p:0.00), early-stage risk score (p:0.007), treatment response (p:0.006) and the latest status of patients (p:0.005). The mean Hb level was found as 13.27 ± 2.20 g/dl in the early stages (1 and 2) and 11.86 ± 2.42 g/dl in the advanced stages. The mean Hb value was 13.93 ± 1.96 g/dl in the group that had early-stage positive prognostic characteristics, while it was found at 12.69 ± 2.29 g/dl in the group of negative risk. This value for the group that responded to the treatment (CR+PR) was Hb 12.65 ± 2.36 g/dl, while the group that did not respond (SD/PD/EF) had a mean value of 11.18 ± 2.54 g/dl. The mean Hb value was found as 12.61 ± 2.38 g/dl in the patients who survived and 10.78 ± 2.37 g/dl in the patients who died (Table-IV).

**DISCUSSION**

Neutrophil/lymphocyte ratio is accepted as a simple and strong parameter related to prognosis in cancer patients for assessing both inflammatory (neutrophil) and immune (lymphocyte) responses. In this context, several studies proved the prognostic significance of NLR, which was check on diagnosis and before treatment, in patients with solid organ tumors.13 It was also shown in

Table-III: NLR with stage, prognostic features, treatment response and relapse status of the relationship

| Stage        | Early Stage | Advanced stage |
|--------------|-------------|----------------|
| NLR          | 3.94        | 5.91           |
| Std. Deviation | 3.70       | 6.56           |
| Z value      | -0.483      |                |
| P value      | 0.013       |                |

| Early stage  | Favorable risk | Unfavorable risk |
|--------------|----------------|-----------------|
| NLR          | 2.77           | 4.58            |
| Std. Deviation | 1.61       | 3.72            |
| Z value      | -2.294         | -0.865          |
| P value      | 0.022          | 0.387           |

| Advanced stage  | Favorable risk | Unfavorable risk |
|-----------------|----------------|-----------------|
| NLR             | 5.12           | 5.96            |
| Std. Deviation  | 2.29           | 6.75            |
| Z value         | -0.865         | -1.710          |
| P value         | 0.387          | 0.87            |

| Treatment response  | CR+PR | SD/PD/EF |
|---------------------|-------|----------|
| NLR                 | 4.97  | 5.63     |
| Std. Deviation      | 5.57  | 4.09     |
| Z value             | -2.142|         |
| P value             | 0.032 |          |

| Recurrence status  | No recurrence | Recurrence |
|--------------------|---------------|------------|
| NLR                | 4.90          | 5.76       |
| Std. Deviation     | 5.35          | 6.55       |
| Z value            | -0.645        |           |
| P value            | 0.519         |           |

| Final status     | Lives | Death |
|------------------|-------|-------|
| NLR              | 5.07  | 4.84  |
| Std. Deviation   | 5.77  | 2.16  |
| Z value          | -1.710|       |
| P value          | 0.87  |       |

Table-IV: Hb with stage, prognostic features, treatment response and relapse status of the relationship

| Stage        | Early Stage | Advanced stage |
|--------------|-------------|----------------|
| Hb           | 13.27       | 11.86          |
| Std. Deviation | 2.20       | 2.42           |
| Z value      | -4.614      |                |
| P value      | 0.000       |                |

| Early stage  | Favorable risk | Unfavorable risk |
|--------------|----------------|-----------------|
| Hb           | 13.93          | 12.69           |
| Std. Deviation | 1.96       | 2.29            |
| Z value      | -2.688         | -1.188          |
| P value      | 0.007          | 0.235           |

| Advanced stage  | Favorable risk | Unfavorable risk |
|-----------------|----------------|-----------------|
| Hb              | 12.78          | 11.80           |
| Std. Deviation  | 1.05           | 2.47            |
| Z value         | -1.188         | -0.597          |
| P value         | 0.235          | 0.532           |

| Treatment response  | CR+PR | SD/PD/EF |
|--------------------|-------|----------|
| Hb                 | 12.65 | 12.18    |
| Std. Deviation     | 2.36  | 2.54     |
| Z value            | -2.273| -1.104   |
| P value            | 0.006 | 0.269    |

| Recurrence status  | No recurrence | Recurrence |
|--------------------|---------------|------------|
| Hb                 | 12.54         | 12.14      |
| Std. Deviation     | 2.48           | 2.15       |
| Z value            | -1.104         |           |
| P value            | 0.269          |           |

| Final status     | Lives | Death |
|------------------|-------|-------|
| Hb               | 12.61 | 10.78 |
| Std. Deviation   | 2.38  | 2.37  |
| Z value          | -2.781|       |
| P value          | 0.005 |       |
hematological malignity cases such as diffuse large B-cell lymphoma that high NLR is related to poor prognosis. The reason for the correlation of NLR with prognosis is largely unknown. In addition to this, it was reported that normal neutrophils may suppress the function of T-cells, and activated neutrophils increase the level of arginase 1, which leads to suppression of T-cells. In addition to contributing to the immune suppression of T-cells, neutrophils may also show characteristics that support tumors such as inducing angiogenesis and increasing tumor metastasis by raising the expression of matrix metalloproteinase.

We also investigated the relationships NLR in cHL at the time of diagnosis had with disease stages, risk scores, treatment responses and statuses of relapse. In our study, the NLR values at the time of diagnosis were found to be higher in the advanced-stage patients, early-stage negative risk group and patients who did not respond to treatment. There was no significant relationship between high NLR values and relapse status.

A study by Marcheselli et al. on 990 nodular sclerosis-cHL patients reported that the value of NLR >6 was associated with both poor progression-free survival (PFS) and overall survival (OS) in both early-stage and advanced-stage cases. When they compared those with NLR >6 and those with NLR ≤6 at the time of diagnosis, they respectively found the 5-year rates of PFS as 75% and 84% and OS as 88% and 92%. A study by Koh et al. that was conducted with 312 cHL patients showed that NLR values of higher than 4.3 were related to poor OS rates in advanced-stage patients. Another study on early-stage cHL found 2-year freedom from progression (FFP) as 82.2% in those with NLR ≥6.4 and 95.7% in those with NLR <6.4, associating high NLR levels with poor FFP. It was not possible in our study to conduct PFS and OS analyses due to the insufficient duration of monitoring.

CONCLUSION

NLR is an inexpensive and easily accessible test whose prognostic significance has been shown in several studies. Although it was not possible in our study to investigate the relationship of NLR with PFS and OS due to the short times of monitoring the patients, we showed that it is related to stage, early-stage risk status and treatment response.

Limitations of the study: It was a study with a retrospective design, the number of cases was small, and it was not possible to conduct PFS and OS analyses due to the insufficient duration of monitoring.

REFERENCES

1. Glaser SL, Jarrett RF. The epidemiology of Hodgkin’s disease. Baillieres Clin Haematol. 1996;9(3):401-416.
2. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390. doi: 10.1182/blood-2016-01-643569.
3. Tubiana M, Henry-Amar M, Carde P, Burgers JM, Hayat M, Van der Schueren E, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin’s disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood. 1989;73(1):47-56.

Deceleration of interest: None.

Funding: None.
4. Diehl V, Stein H, Hummel M, Zollinger R, Connors JM. Hodgkin’s lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology Am Soc Hematol Educ Program. 2003;225-247.

5. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med. 1998;339(21):1506-1514. doi: 10.1056/NEJM199811193392104.

6. Porrata LF, Ristow K, Habermann T, Inwards DJ, Micallef IN, Markovic SN. Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio. Am J Hematol. 2010;85(11):896-899. doi:10.1002/ajh.21849.

7. Ho CL, Lu CS, Chen JH, Chen YG, Huang TC, Wu YY. Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era. Medicine (Baltimore). 2015;94(24):e993. doi:10.1097/MD.0000000000000993.

8. Keam B, Ha H, Kim TM, Jeon YK, Lee SH, Kim DW, et al. Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Leuk Lymphoma. 2015;56(7):2032-2038. doi:10.3109/10428194.2014.982642.

9. Koh YW, Kang HJ, Park C, Yoon DH, Kim S, Suh C, et al. Prognostic significance of the ratio of absolute neutrophil count to absolute lymphocyte count in classic Hodgkin lymphoma. Am J Clin Pathol. 2012;138(6):846-854. doi:10.1309/AJCP04GFKGNXCBR.

10. Marcheselli R, Bari A, Tadmor T, Marcheselli L, Cox MC, Pozzi S, et al. Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients. Hematol Oncol. 2017;35(4):561-566. doi:10.1002/hon.2359.

11. Reddy JP, Hernandez M, Gunther JR, Dabaja BS, Martin GV, Jiang W, et al. Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma. Br J Haematol. 2018;180(4):545-549. doi: 10.1111/bjh.15054.

12. Cosset JM, Henry-Amar M, Meurwaldt JH, Carde P, Noordijk EM, Thomas J, et al. The EORTC trials for limited stage Hodgkin’s disease. The EORTC Lymphoma Cooperative Group. Eur J Cancer. 1992;28A(11):1847-1850.

13. Nishijima TF, Muss HB, Shachar SS, Tamura K, Takamatsu Y. Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: A systematic review and meta-analysis. Cancer Treat Rev. 2015;41(10):971-978. doi: 10.1016/j.ctrv.2015.10.003.

14. Troppan K, Deutsch A, Gerger A, Stojakovic T, Beham-Schmid C, Wenzl K, et al. The derived neutrophil to lymphocyte ratio is an independent prognostic factor in patients with diffuse large B-cell lymphoma. Br J Cancer. 2014;110(2):369-374. doi: 10.1038/bjc.2013.763.

15. Melchardt T, Troppan K, Weiss L, Hufnagl C, Neureiter D, Tranekerschuh W, et al. Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI. J Natl Compr Canc Netw. 2015;13(12):1501-1508.

16. Munder M, Schneider H, Luckner C, Giese T, Langhans CD, Fuentes JM, et al. Suppression of T-cell functions by human granulocyte arginase. Blood. 2006;108(8):1627-1634. doi: 10.1182/blood-2006-11-010389.

17. Romano A, Parrinello NL, Vetro C, Chiarenza A, Cerchione C, Ippolito M, et al. Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ratio (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy. Ann Hematol. 2018;97(6):1099-1018. doi: 10.1007/s00277-018-3276-y.